

- **Full Name:** Miso Kim
  - **Current Position & Affiliation:** Clinical Associate Professor, Seoul National University Hospital
  - **Country:** Republic of Korea
- 

**• Educational Background:**

- 2009 M.D. / College of Medicine, Seoul National University
- 2014 M.S. / College of Medicine, Seoul National University
- 2021 Ph.D. / College of Medicine, Seoul National University

**• Professional Experience:**

- 2010-2014 Residency, Internal Medicine, Seoul National University Hospital
- 2014-2015 Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- 2015-2016 Clinical Instructor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital
- 2016-2021 Clinical Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital
- 2021-present Clinical Associate Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital

**• Professional Organizations:**

- Korean Medical Association
- Korean Association of Internal Medicine
- Korean Society of Medical Oncology
- Korean Cancer Association
- Korean Association for Lung Cancer
- European Society for Medical Oncology
- American Society of Clinical Oncology

**• Main Scientific Publications:**

1. Kim CG, **Kim M**, Hwang J, Kim ST, Jung M, Kim KH et al. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma. *J Am Acad Dermatol.* 2022 Nov;87(5):989-996. (co-1<sup>st</sup> author)
2. Jung HA, **Kim M**, Kim HS, Kim JH, Choi YH, Cho J, et al. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21). *J Thorac Oncol.* 2023 Feb;18(2):223-231. (co-1<sup>st</sup> author)
3. Lee C, **Kim M**, Kim DW, Kim TM, Kim S, Im SW, et al. Acquired Resistance Mechanism of *EGFR* Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer. *Cancer Res Treat.* 2022 Jan;54(1):140-149. (co-1<sup>st</sup> author)

4. Park C, **Kim M**, Kwak Y, Moon KC, Kim SH, Keam B, et al. Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. *Cancer Res Treat*. 2021 Oct;53(4):1195-1203. (corresponding author)
5. **Kim M**, Lee JO, Koh J, Kim TM, Lee JY, Jeon YK, et al. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. *Haematologica*. 2021 Aug 1;106(8):2277-2280.
6. **Kim M**, Keam B, Ock CY et al. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07. *Thorac Cancer* 2020;11(12):3482-3489.
7. Park C, **Kim M**, Kim MJ et al. Clinical Application of Next-Generation Sequencing-Based Panel to *BRAF* Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. *Mol Cancer Ther* 2020;19:937-944. (corresponding author)
8. **Kim M**, Kim TM, Keam B et al. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. *Oncologist* 2019;24:20-e29.